Pfizer Inc (PFE)

$29.02 +0.47 (1.65%)
Market Cap 162.73B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 9.33
Forward PE 9.56
Profit Margin 12.42%
Debt to Equity Ratio 0.74
Volume 39,277,900
Avg Vol 41,664,922
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 95%
Beta 0.34
Analysts Sell
Price Target $28.60

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
StocktwitsNews
StocktwitsNews Sep. 3 at 4:51 AM
Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today? $PFE $GTLB $COP https://stocktwits.com/news/equity/markets/why-did-pfe-gtlb-cop-stocks-jump-to-52-week-highs-today/cZsMZSZRJHp
0 · Reply
jrh34
jrh34 Sep. 3 at 3:20 AM
$PFE is back in vogue. Makes $45-50 range achievable this year. I like the upside potential, especially with the rotation out of tech in Pharma.
1 · Reply
Agent8
Agent8 Sep. 3 at 2:43 AM
$PFE “The study tests PF-08103402, an oral drug given as a suspension or tablet, used once daily in most parts of the trial. It aims to manage asthma better by tracking how the drug moves through the body and interacts with food and other medicines, using placebo and a known drug, midazolam, as comparators in selected groups.” https://www.tipranks.com/news/company-announcements/pfizers-new-asthma-candidate-pf-08103402-enters-phase-1-what-investors-should-know#google_vignette LT
0 · Reply
TalkMarkets
TalkMarkets Sep. 2 at 11:26 PM
Did The #COVID Vaccine Ruin #Pfizer’s 6.1% Yield? $PFE https://talkmarkets.com/article/did-the-covid-vaccine-ruin-pfizers-61-yield-1788391565
0 · Reply
CapitalMonk
CapitalMonk Sep. 2 at 10:24 PM
$PFE Price: $29.02 (+1.65%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.57% RSI: 77.5 | Momentum: Moderate Volume: +3.3% vs avg Volatility: 1.44% Support: $25.30 | Resistance: $29.09 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
Outcomes
Outcomes Sep. 2 at 9:20 PM
$IBRX $MRNA $MRK $PFE $JNJ https://x.com/stkirsch/status/2094989788919267745?s=46
0 · Reply
Outcomes
Outcomes Sep. 2 at 9:12 PM
$IBRX $MRNA.X $MRK $PFE $JNJ …alotta opinions on Makis, but WOW! https://x.com/makismedicine/status/2095156284513284405?s=46
1 · Reply
SniperPro
SniperPro Sep. 2 at 8:12 PM
$LXRX $NVO $VTRS $PFE $MRK 🤔 Who’s going to be Lexicon’s next partner? With Lexicon Pharmaceuticals building momentum and its pipeline attracting attention, the big question is: who could be next to partner with Lex? Could it be $NVO $VTRS $PFE or $MRK ? The right partnership could be a major catalyst for $LXRX. 👀 Speculation for now—but it’s definitely worth watching closely. Who do you think is next? 🔥 Why are shorts covering? What do they know? TICK TOCK!!!!
1 · Reply
goguryo2000
goguryo2000 Sep. 2 at 8:07 PM
$PFE This is 3rd time it hit 29 and first time ended with 29 mark. 30 might come sooner than expected. Looking forward to see good old 35s and 36s.
1 · Reply
alexquick123
alexquick123 Sep. 2 at 7:47 PM
$PFE
0 · Reply
Latest News on PFE
Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

Sep 2, 2026, 9:00 AM EDT - 18 hours ago

Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities

XRAY

Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

Aug 31, 2026, 1:20 PM EDT - 2 days ago

Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers

LLY NVO TAK

Trump administration to announce drug pricing deals

Aug 31, 2026, 12:09 PM EDT - 2 days ago

Trump administration to announce drug pricing deals

AMGN LLY TAK

US FDA approves updated COVID vaccines for 2026-27 season

Aug 27, 2026, 5:48 PM EDT - 6 days ago

US FDA approves updated COVID vaccines for 2026-27 season

MRNA NVAX SNY BNTX

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

2026-08-27T20:35:15.000Z - 6 days ago

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

BNTX

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Aug 27, 2026, 4:30 PM EDT - 6 days ago

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

BNTX

White House to announce new drug pricing deals with biotechs, Bloomberg News reports

Aug 26, 2026, 12:48 PM EDT - 7 days ago

White House to announce new drug pricing deals with biotechs, Bloomberg News reports

AMGN LLY

Pfizer Stock (PFE) Is a Buy despite Declining Revenue

2026-08-24T12:18:00.000Z - 9 days ago

Pfizer Stock (PFE) Is a Buy despite Declining Revenue

Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update

2026-08-19T14:35:12.000Z - 14 days ago

Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update

BNTX MRK MRNA

Pfizer, Valneva announce EMA validation for PF-07307405 MAA

2026-08-16T13:55:21.000Z - 17 days ago

Pfizer, Valneva announce EMA validation for PF-07307405 MAA

VALN

Pfizer (PFE) CEO Buys $1 Million of Company Stock

2026-08-14T18:45:04.000Z - 19 days ago

Pfizer (PFE) CEO Buys $1 Million of Company Stock

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Aug 14, 2026, 1:45 PM EDT - 19 days ago

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Closed Pfizer biopharma facility in Everett gets a new lease on life

Aug 14, 2026, 11:46 AM EDT - 19 days ago

Closed Pfizer biopharma facility in Everett gets a new lease on life

Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money

Aug 14, 2026, 11:11 AM EDT - 19 days ago

Pfizer is paying $44 million to settle a Chantix lawsuit. See who could get money

Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes

2026-08-14T13:47:35.000Z - 19 days ago

Valneva Stock (VALN) Soars Over 20% On Lyme Disease Vaccine Hopes

VALN

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Aug 14, 2026, 1:00 AM EDT - 20 days ago

Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

VALN

Pfizer Earnings Call Transcript: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Earnings Call Transcript: Q2 2026

Pfizer Earnings release: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Earnings release: Q2 2026

Pfizer Slides: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Slides: Q2 2026

Pfizer Quarterly report: Q2 2026

Aug 4, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Quarterly report: Q2 2026

Pfizer Post Loss on Higher Revenue

Aug 4, 2026, 7:24 AM EDT - 4 weeks ago

Pfizer Post Loss on Higher Revenue

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Aug 4, 2026, 7:13 AM EDT - 4 weeks ago

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

Aug 4, 2026, 7:12 AM EDT - 4 weeks ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

BNTX

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Aug 4, 2026, 6:52 AM EDT - 4 weeks ago

Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Aug 4, 2026, 6:45 AM EDT - 4 weeks ago

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Jul 30, 2026, 7:48 AM EDT - 4 weeks ago

Pfizer's oral drug restores skin pigmentation in late-stage vitiligo trials

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Jul 30, 2026, 6:45 AM EDT - 4 weeks ago

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Jul 29, 2026, 4:30 PM EDT - 5 weeks ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

BNTX

Pfizer's prostate cancer drug combination gets US FDA priority review

Jul 22, 2026, 4:48 PM EDT - 6 weeks ago

Pfizer's prostate cancer drug combination gets US FDA priority review

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Jul 22, 2026, 4:30 PM EDT - 6 weeks ago

FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

Jul 21, 2026, 7:10 PM EDT - 6 weeks ago

Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later

LLY

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Jul 16, 2026, 1:39 PM EDT - 6 weeks ago

Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Jul 10, 2026, 11:23 AM EDT - 7 weeks ago

U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 1 month ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

Jun 29, 2026, 4:43 PM EDT - 2 months ago

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

ABT ADM APD BAC CMCSA CVS DIS

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Jun 29, 2026, 1:20 AM EDT - 2 months ago

Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 2 months ago

Pfizer Declares Third-Quarter 2026 Dividend

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Jun 24, 2026, 2:10 PM EDT - 2 months ago

FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 2 months ago

Pfizer dismissed from US states' drug price-fixing lawsuit

China outpacing Europe in drug innovation and development, Pfizer executive says

Jun 23, 2026, 12:10 PM EDT - 2 months ago

China outpacing Europe in drug innovation and development, Pfizer executive says

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Jun 23, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts

Pfizer's experimental drug misses main goal of lung cancer trial

Jun 22, 2026, 4:43 PM EDT - 2 months ago

Pfizer's experimental drug misses main goal of lung cancer trial

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Jun 22, 2026, 4:30 PM EDT - 2 months ago

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

Jun 22, 2026, 2:32 PM EDT - 2 months ago

Wall Street loves growth stocks — but these 10 ‘losers' are primed to win

ACHR AGCO COF DHI DVN EOG TSN

Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 2 months ago

Pfizer CFO Dave Denton to step down, leave company in August

Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Chief Financial Officer Transition

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 10, 2026, 7:56 AM EDT - 2 months ago

Pfizer CEO warns German investment at risk over drug pricing policies

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

Jun 9, 2026, 2:07 PM EDT - 2 months ago

Want to Avoid the Whipsawing Tech Stocks? Dollar General and 7 Others to Buy.

DG ALGN BBY BIIB CVS VZ

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY MRK NVO

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 2 months ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY MRK RDW UTHR XBI

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 2 months ago

US FDA approves Pfizer's bleeding disorder drug for children

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Jun 8, 2026, 6:45 AM EDT - 2 months ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Transcript: Study update

Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Slides: Study update

Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 2 months ago

Pfizer Press release: Study update

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Jun 6, 2026, 9:06 AM EDT - 2 months ago

Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Jun 6, 2026, 9:00 AM EDT - 2 months ago

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Jun 4, 2026, 10:00 AM EDT - 3 months ago

Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

Jun 4, 2026, 6:40 AM EDT - 3 months ago

Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup

LLY

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 2:00 PM EDT - 3 months ago

Pfizer Transcript: Jefferies Global Healthcare Conference 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jun 1, 2026, 10:00 AM EDT - 3 months ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

May 31, 2026, 8:00 AM EDT - 3 months ago

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

May 30, 2026, 8:00 AM EDT - 3 months ago

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

StocktwitsNews
StocktwitsNews Sep. 3 at 4:51 AM
Why Did PFE, GTLB, COP Stocks Jump To 52-Week Highs Today? $PFE $GTLB $COP https://stocktwits.com/news/equity/markets/why-did-pfe-gtlb-cop-stocks-jump-to-52-week-highs-today/cZsMZSZRJHp
0 · Reply
jrh34
jrh34 Sep. 3 at 3:20 AM
$PFE is back in vogue. Makes $45-50 range achievable this year. I like the upside potential, especially with the rotation out of tech in Pharma.
1 · Reply
Agent8
Agent8 Sep. 3 at 2:43 AM
$PFE “The study tests PF-08103402, an oral drug given as a suspension or tablet, used once daily in most parts of the trial. It aims to manage asthma better by tracking how the drug moves through the body and interacts with food and other medicines, using placebo and a known drug, midazolam, as comparators in selected groups.” https://www.tipranks.com/news/company-announcements/pfizers-new-asthma-candidate-pf-08103402-enters-phase-1-what-investors-should-know#google_vignette LT
0 · Reply
TalkMarkets
TalkMarkets Sep. 2 at 11:26 PM
Did The #COVID Vaccine Ruin #Pfizer’s 6.1% Yield? $PFE https://talkmarkets.com/article/did-the-covid-vaccine-ruin-pfizers-61-yield-1788391565
0 · Reply
CapitalMonk
CapitalMonk Sep. 2 at 10:24 PM
$PFE Price: $29.02 (+1.65%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.57% RSI: 77.5 | Momentum: Moderate Volume: +3.3% vs avg Volatility: 1.44% Support: $25.30 | Resistance: $29.09 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
0 · Reply
Outcomes
Outcomes Sep. 2 at 9:20 PM
$IBRX $MRNA $MRK $PFE $JNJ https://x.com/stkirsch/status/2094989788919267745?s=46
0 · Reply
Outcomes
Outcomes Sep. 2 at 9:12 PM
$IBRX $MRNA.X $MRK $PFE $JNJ …alotta opinions on Makis, but WOW! https://x.com/makismedicine/status/2095156284513284405?s=46
1 · Reply
SniperPro
SniperPro Sep. 2 at 8:12 PM
$LXRX $NVO $VTRS $PFE $MRK 🤔 Who’s going to be Lexicon’s next partner? With Lexicon Pharmaceuticals building momentum and its pipeline attracting attention, the big question is: who could be next to partner with Lex? Could it be $NVO $VTRS $PFE or $MRK ? The right partnership could be a major catalyst for $LXRX. 👀 Speculation for now—but it’s definitely worth watching closely. Who do you think is next? 🔥 Why are shorts covering? What do they know? TICK TOCK!!!!
1 · Reply
goguryo2000
goguryo2000 Sep. 2 at 8:07 PM
$PFE This is 3rd time it hit 29 and first time ended with 29 mark. 30 might come sooner than expected. Looking forward to see good old 35s and 36s.
1 · Reply
alexquick123
alexquick123 Sep. 2 at 7:47 PM
$PFE
0 · Reply
Stockmaster198
Stockmaster198 Sep. 2 at 7:41 PM
$PFE it’s confirmed after market closed this will run past 100%
1 · Reply
Sb2001
Sb2001 Sep. 2 at 7:26 PM
$PFE sloooowly I step, inch by inch.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 2 at 7:20 PM
$AZN $JNJ $MRK $PFE $SLS Shorts are pushing Dr. Stergiou to the brink and he might potentially release the GPS CURATIVE KRAKEN after the bell and wipe out cancer along with the shorts! ✌️🙏❤️‍🩹
0 · Reply
BB_88_
BB_88_ Sep. 2 at 7:14 PM
$PFE
0 · Reply
WuTangClam
WuTangClam Sep. 2 at 6:58 PM
$PFE & $KHC $VZ .. dividend pick ups that were hard to miss with their monster dividends. Hopefully everybody was listening
0 · Reply
BWinner
BWinner Sep. 2 at 6:53 PM
$PFE $29!!!!!
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Sep. 2 at 6:50 PM
$PFE Really thought id sell the next time we got back here. But here I am deciding to stay. I have learned nothing and I am ready to get hurt again!
3 · Reply
jrh34
jrh34 Sep. 2 at 5:58 PM
$PFE Hot stock lately, let's see them get a deal on with $CRDF for Onvansertib in mCRC.
0 · Reply
zustrelaax
zustrelaax Sep. 2 at 5:56 PM
$PFE need catalyst to move 32 and next 36
0 · Reply
Fliptax
Fliptax Sep. 2 at 5:51 PM
$PFE $33-35 next stop
0 · Reply
jrh34
jrh34 Sep. 2 at 5:33 PM
$PFE is back in favor, which means $45-50 range is obtainable over the coming months.
0 · Reply
Willieberich
Willieberich Sep. 2 at 5:28 PM
$PFE break 29 on the close 30 is coming right away
0 · Reply